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Acne Vaccines: Therapeutic Option 
for the Treatment of Acne Vulgaris?
Jenny Kim1
Acne, one of the most common skin diseases, is caused by multiple factors, 
including Propionibacterium acnes. Studies suggest that responses to P. acnes by 
host immunity play important roles in its pathogenesis. Identifying immune mod-
ulators that attenuate inflammatory responses against P. acnes and the inhibition 
of bacterial growth may lead to novel avenues of immunologic intervention.
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Acne vulgaris is one of the most com-
mon skin diseases, affecting approxi-
mately 50 million people in the United 
States. The disease is important because 
it has significant morbidity and pro-
foundly affects patients’ self-esteem. 
Although acne is common, its patho-
genesis is still uncertain. Multiple 
etiological factors, including fol-
licular hyperkeratinization, sebum, 
Propionibacterium acnes, and inflam-
mation, are thought to contribute. 
Perhaps it is the multifactorial etiol-
ogy of acne that makes it challenging 
to treat. There is a high unmet clinical 
need for new and better treatments, 
given the increase in antibiotic-resistant 
strains of P. acnes and the restrictions 
placed on the use of isotretinoin. In this 
issue, Nakatsuji et al. (2008b) describe 
an alternative strategy to conventional 
therapy: a P. acnes vaccine that exerts 
protective immunity.
Although P. acnes is present in normal 
skin, its importance in acne pathogene-
sis has been well demonstrated because 
a reduction in bacterial count with 
antibiotic therapy improves the clinical 
outcome. What is less clear, however, 
is whether P. acnes is a true pathogen 
or whether unwanted host immune 
responses to this commensal microbe 
determine the disease outcome, 
because the number of bacteria pres-
ent in lesions does not always correlate 
with disease severity (Leyden et al., 
1988). Several previous studies have 
demonstrated that both cellular and 
humoral immunity against P. acnes are 
present in patients, and recent studies 
have provided a better understanding of 
the innate immune response produced 
by hosts in response to P. acnes. Upon 
activation, host innate cells elaborate 
a protective antimicrobial response to 
P. acnes by inducing the production of 
antimicrobial peptides such as human 
β-defensin 2 (Nagy et al., 2005, 2006). 
On the other hand, the same mecha-
nism may be responsible for producing 
inflammatory mediators by innate cells 
such as keratinocytes, monocytes, and 
sebocytes in response to P. acnes (Kim 
et al., 2002; Nagy et al., 2005, 2006), 
causing tissue injury and inflamma-
tory disease. The balance between these 
innate responses, in addition to adaptive 
immune responses elicited by P. acnes 
likely determines whether the host will 
present with clinically active lesions.
Many of the current therapies focus 
on reducing the number of P. acnes 
organisms, and most recent develop-
ments have been in the use of combi-
nation therapies. Benzoyl peroxide and 
the retinoids have been added to topi-
cal antibiotics with the hope that the 
frequency of resistance will decrease, 
thereby improving the therapeutic out-
come. On the other hand, only a few 
therapies focus primarily on reducing 
inflammation. The use of lower doses of 
antibiotics for their anti-inflammatory 
properties is currently being evalu-
ated. In addition, recent studies sug-
gest that in addition to its well-known 
effect on “normalizing” the follicular 
epithelium, retinoic acid demonstrates 
anti-inflammatory and antimicrobial 
effects (Liu et al., 2005, 2008), under-
scoring the need to investigate further 
the immunomodulatory effects of acne 
therapies. Despite substantial interest in 
basic acne research, acne vaccines that 
modulate host immune responses to 
P. acnes are not available.
In the study reported in this issue, 
Nakatsuji et al. (2008b) generated 
antibodies using inactivated P. acnes, 
postulating that they might provide 
protective immunity. The authors dem-
onstrated that intranasal immunization 
of mice with this inactivated vaccine 
generated in vivo protective immunity 
against P. acnes challenge. Specifically, 
the antibodies elicited by inactivated 
P. acnes attenuated IL-8 production 
in human sebocytes; however, there 
was no effect on P. acnes growth. The 
clinical improvement observed in this 
P. acnes inflammatory murine model 
suggests that for acne treatment, anti-
bodies that primarily exhibit anti-
inflammatory properties might be suf-
ficient for clinical improvement but 
without an antimicrobial effect.
The inactivated P. acnes vaccine used 
in this study targeted the whole bacte-
rium, most likely without specificity. 
Therefore, developing vaccines against 
specific P. acnes antigens might be 
even more useful, as previously dem-
onstrated by the same research group 
(Nakatsuji et al., 2008a). This would 
require that P. acnes antigens first be 
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identified and then characterized for 
the types of response that each anti-
gen elicits; this information could then 
be used to develop a component acne 
vaccine. Very few P. acnes antigens 
have been identified and studied.
It will be important to evalu-
ate the antibodies generated against 
P. acnes for other immunomodulatory 
effects, including their ability to induce 
pro inflammatory mediators and cyto-
toxicity, which might lead to tissue inju-
ry. It has been shown that some patients 
have antibodies against P. acnes, and 
positive correlations between antibody 
titers and the severity of the disease 
have been reported (Ashbee et al.,1997; 
Ingham et al.,1987; Webster et al., 
1985). Thus, not all antibodies directed 
against P. acnes may be beneficial, and 
they may even worsen the disease.
Part of the difficulty in develop-
ing any acne therapy is that there is 
no perfect animal model. Although 
the mouse model used by Nakatsuji 
et al. (2008b) demonstrated a decrease 
in ear swelling in vaccinated mice, 
the lesions produced by injection 
of P. acnes into the ears of mice do 
not reproduce clinical acne lesions 
exactly. For this reason, it is not cer-
tain that similar clinical improvement 
will occur in humans, in whom other 
varying factors, such as the presence 
of inflammatory lipids in sebum, may 
influence the growth and behavior of 
P. acnes. Nonetheless, the authors 
of this study offer an important and 
interesting concept—that focusing 
on attenuating the inflammatory 
component of the disease could be 
therapeutically beneficial. Because 
the induction of cytokines, chemo-
kines, and metalloproteinases by 
P. acnes occurs via a Toll-like receptor 2 
(TLR2)-dependent pathway, the devel-
opment of vaccines or other immune 
therapies that target TLR2 and other 
TLRs may provide other alternatives to 
conventional therapy. We are already 
familiar with agents that modulate TLR 
response, such as imiquimod, which 
enhances TLR7 and TLR8 function, 
and retinoic acid, which downregu-
lates TLR2 expression and function, 
suggesting that vaccines with potent 
anti-TLR immunity may hold promise 
for the future of acne therapy.
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Germline MC1R Variants  
and BRAF Mutant Melanoma
Elke Hacker1 and Nicholas K. Hayward1
Recent studies have demonstrated that melanocortin-1 receptor (MC1R) variants 
increase the risk of melanomas harboring BRAF mutations. This finding provides 
insight into the relationship between host genotype and selection for somatic 
mutation type. Additional larger studies are required in diverse populations to 
further examine the interaction between MC1R and BRAF in different melanoma 
subtypes.
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mc1r function
MC1R is a well-known G-protein-
coupled receptor found on melanocytes 
that plays an important role in the reg-
ulation of pigmentation (reviewed in 
Abdel-Malek et al., 2008). The gene is 
highly polymorphic, with more than 
60 variants documented, the major-
ity of which compromise the function 
of the receptor so that it inadequately 
responds to its ligands, α-melanocyte-
stimulating hormone (α-MSH) and 
β-defensin (Abdel-Malek et al., 2008, 
Candille et al., 2007). Variant MC1R 
isoforms affect the signal transduction 
pathways that normally result in a switch 
from pheomelanin to eumelanin pro-
duction after exposure of skin to UVR 
(Abdel-Malek et al., 2008). They are 
also strongly associated with red hair 
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